These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886 [TBL] [Abstract][Full Text] [Related]
25. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study. Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266 [TBL] [Abstract][Full Text] [Related]
26. Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Kümpers C; Jokic M; Haase O; Offermann A; Vogel W; Grätz V; Langan EA; Perner S; Terheyden P Front Med (Lausanne); 2019; 6():27. PubMed ID: 30931305 [TBL] [Abstract][Full Text] [Related]
27. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697 [TBL] [Abstract][Full Text] [Related]
28. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Tomela K; Pietrzak B; Schmidt M; Mackiewicz A Life (Basel); 2020 Sep; 10(10):. PubMed ID: 32992737 [TBL] [Abstract][Full Text] [Related]
29. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. Jessurun CAC; Vos JAM; Limpens J; Luiten RM Front Oncol; 2017; 7():233. PubMed ID: 29034210 [TBL] [Abstract][Full Text] [Related]
31. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649 [TBL] [Abstract][Full Text] [Related]
32. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center. Afzal MZ; Shirai K Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753 [TBL] [Abstract][Full Text] [Related]
34. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107 [TBL] [Abstract][Full Text] [Related]
35. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Hermel DJ; Ott PA Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070 [TBL] [Abstract][Full Text] [Related]
37. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma. Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176 [TBL] [Abstract][Full Text] [Related]
38. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757 [TBL] [Abstract][Full Text] [Related]
39. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946 [TBL] [Abstract][Full Text] [Related]